Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Hylenex Recombinant,  mphadase, Vitrase
Synonyms :
hyaluronidase
Class :
Extravasation Antidotes
Brand Name :
Hylenex Recombinant,  mphadase, Vitrase
Synonyms :
hyaluronidase
Class :
Extravasation Antidotes
Dosage Forms & StrengthsÂ
Injectable solutionÂ
150 units/mlÂ
200 units/mlÂ
To the injectable solution, add 50 to 300 units, usually about 150 units
Intradermal injection of 0.02 mL (3 units) of a 150 units/mL solution can produce a positive hypersensitive reaction if a wheal with pseudopods appears within 5 minutes and lasts 20 to 30 minutes along with itching
Adjunct Subcutaneous UrographyÂ
Beneficial for radiopaque agent absorption, especially in cases when prone patient positioning prevents intravenous delivery
Before injecting the contrast medium, inject 75 units sub cutaneous over each scapula
Vitrase: Before giving an intravenous (IV) infusion of 1000 mL or more of the solution, inject 200 units subcutaneously (SC)
Hylenex/Amphadase: To improve the absorption of 1000 mL or more of the solution, inject 150 units just before subcutaneous fluid delivery
Dosage Forms & StrengthsÂ
Injectable solutionÂ
150 units/mlÂ
200 units/mlÂ
Intradermal injection of 0.02 mL (3 units) of a 150 units/mL solution can produce a positive hypersensitive reaction if a wheal with pseudopods appears within 5 minutes and lasts 20 to 30 minutes along with itching
Three years above children: Suitable for use in low-volume solutions (200 mL), such as subcutaneous (SC) injection medication solutions and other similar preparations
Infants and children under three years: The recommended maximum volume for a single clysis is 200 mL.
Dosage for newborns and babies should not exceed 25 mL/kg per day, and the rate of administration should not exceed 2 mL/min
Adjunct Subcutaneous UrographyÂ
Beneficial for radiopaque agent absorption, especially in cases when prone patient positioning prevents intravenous delivery.
Before injecting the contrast medium, inject 75 units sub cutaneous over each scapula.
Refer adult dosingÂ
may increase the vasoconstricting effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may increase the toxic effect of hyaluronidase
It may increase the vasoconstricting effect when combined with Alpha-/Beta-Agonists
It may increase the vasoconstricting effect when combined with Alpha-/Beta-Agonists
It may increase the vasoconstricting effect when combined with Alpha-/Beta-Agonists
It may increase the vasoconstricting effect when combined with Alpha-/Beta-Agonists
It may increase the vasoconstricting effect when combined with Alpha-/Beta-Agonists
may increase the immunosuppressive effect of corticosteroids
may decrease the therapeutic effect
It may increase the adverse effect when combined with hyaluronidase
acetaminophen, pheniramine, and phenylephrineÂ
may have an increased vasoconstricting effect when combined with phenylephrine
It may diminish the effect when combined with beclomethasone, inhaled by unspecified interactions mechanism
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
hyaluronidase: they may decrease the therapeutic effect of antihistamines
hyaluronidase: they may decrease the therapeutic effect of antihistamines
hyaluronidase: they may decrease the therapeutic effect of antihistamines
hyaluronidase: they may decrease the therapeutic effect of antihistamines
hyaluronidase: they may decrease the therapeutic effect of antihistamines
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of hyaluronidase
choline magnesium trisalicylate
may decrease the therapeutic effect of hyaluronidase
hyaluronidase: they may increase the CNS depressant effect of CNS Depressants
hyaluronidase: they may increase the CNS depressant effect of CNS Depressants
hyaluronidase: they may increase the CNS depressant effect of CNS Depressants
hyaluronidase: they may increase the CNS depressant effect of CNS Depressants
hyaluronidase: they may increase the CNS depressant effect of CNS Depressants
salicylates reduce the efficacy of hyaluronidase
may increase the toxic effect of Local Anesthetics
etonogestrel/ethinyl estradiolÂ
may diminish the therapeutic effect of estrogen derivatives
corticosteroids decrease the effect of hyaluronidase
Actions and Spectrum:Â
hyaluronidase is an enzyme that breaks down hyaluronic acid, a large polysaccharide in connective tissue, extracellular matrix, and synovial fluid. The breakdown of hyaluronic acid by hyaluronidase reduces the viscosity of these fluids and tissues, allowing for easier diffusion of fluids and molecules.Â
hyaluronidase has a broad spectrum of activity and can break down hyaluronic acid in various tissues throughout the body. In medical applications, it is often used as an adjuvant to enhance the dispersion and absorption of other injected drugs, such as local anesthetics or antibiotics.Â
Frequency definedÂ
<1%Â
UrticariaÂ
Allergic reactions (<0.1%)Â
AngioedemaÂ
Frequency not definedÂ
Local injection site reactionsÂ
EdemaÂ
Contraindications/caution:Â
Contraindications:Â
Caution:Â
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
Pharmacodynamics:Â
The pharmacodynamics of hyaluronidase are primarily related to its enzymatic activity and its effects on the extracellular matrix.Â
Pharmacokinetics:Â
AbsorptionÂ
hyaluronidase is typically administered via injection. It is rapidly absorbed into the circulation following injection and begins to exert its enzymatic activity soon after. Â
DistributionÂ
hyaluronidase has a widespread distribution throughout the body due to its systemic absorption. The enzyme distributes to various tissues throughout the body, where it acts to break down hyaluronic acid. Â
MetabolismÂ
hyaluronidase is primarily metabolized in the liver through enzymatic cleavage. The exact metabolic pathway of hyaluronidase needs to be better characterized. Â
Elimination and ExcretionÂ
hyaluronidase is excreted primarily in the urine. The elimination half-life of hyaluronidase is relatively short, with a range of approximately 2-3 hours.Â
Administration:Â
hyaluronidase is typically administered via injection. The specific administration technique and dosage depend on the clinical indication and co-administered medication.Â
Patient information leafletÂ
Generic Name: hyaluronidaseÂ
Why do we use hyaluronidase?Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
